Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

Aim: To confirm the efficacy of vildagliptin in patients with type 2 diabetes (T2D) by testing the hypothesis that glycosylated haemoglobin (HbA1c) reduction with vildagliptin is superior to that with voglibose after 12 weeks of treatment.

• Publication year

  2010

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2010.01222.xPMID 20590747PMCID 2916214
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.

  2009cited by this paper
• Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality.

  2009cited by this paper
• Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database

  2008cited by this paper
• The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

  2008cited by this paper
• Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus *

  2008cited by this paper
• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea *

  2008cited by this paper
• Guideline for management of postmeal glucose.

  2008cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Management of Type 2 Diabetes in Treatment-Naive Elderly Patients

  2007cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Voglibose (Basen®, AO-128), One of the Most Important α-Glucosidase Inhibitors

  2006cited by this paper
• Postprandial hyperglycaemia and vascular damage - the benefits of acarbose

  2006cited by this paper
• Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.

  2006cited by this paper
• The importance of tight glycemic control.

  2005influential reference
• Oral antihyperglycemic therapy for type 2 diabetes mellitus

  2005influential reference
• Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.

  2005cited by this paper
• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  2005cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004influential reference
• Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

  2004cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Comparison of the effects of acarbose and voglibose in healthy subjects.

  1997cited by this paper
• Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

  1996cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Effect of Teneligliptin in comparison with Voglibose as an add on therapy in reducing microvascular complications in type II Diabetes Mellitus patients – A Prospective randomized control trial

  2023cites this paper
• Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report

  2021cites this paper
• The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial

  2021cites this paper
• Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis

  2021cites this paper
• Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis

  2020cites this paper
• Specificity of transaminase activities in the prediction of drug-induced hepatotoxicity.

  2020cites this paper
• Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study

  2019cites this paper
• Comparative Evaluation of Safety and Efficacy of Pioglitazone versus Voglibose on Lipid Level in Prediabetes Patient Add on Metformin

  2019cites this paper
• Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial

  2019cites this paper
• Comparative evaluation of Pioglitazone versus Voglibose on glycemic control in patients with Type 2 Diabetes Mellitus on Metformin

  2018cites this paper
• Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations

  2017cites this paper
• Management of type 2 diabetes mellitus: insights into prescribing trends

  2017cites this paper
• Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

  2017cites this paper
• Voglibose: An Important Drug for Type 2 Diabetes

  2017cites this paper
• Structural and Vibrational Studies (FT-IR, FT-Raman) of Voglibose Using DFT Calculation

  2016cites this paper
• Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study

  2016cites this paper
• Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.

  2016cites this paper
• Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.

  2016cites this paper
• Adamantane - A Lead Structure for Drugs in Clinical Practice.

  2016cites this paper
• Socioeconomic Position and Premature Mortality in the AusDiab Cohort of Australian Adults.

  2016cites this paper
• Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.

  2016cites this paper
• Does the treatment of type 2 diabetes mellitus with the Dpp-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

  2016cites this paper
• Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

  2016cites this paper
• Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes

  2016cites this paper
• Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials

  2016cites this paper
• Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients

  2016cites this paper
• Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis

  2016cites this paper
• Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study

  2016cites this paper
• A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor

  2016cites this paper
• A comparative study of efficacy and safety of vildagliptin against metformin in newly diagnosed patients of type 2 diabetes mellitus

  2016cites this paper
• Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.

  2015cites this paper
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

  2015cites this paper
• Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients

  2015cites this paper
• A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

  2015cites this paper
• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  2015cites this paper
• Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis

  2015cites this paper
• Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients

  2015cites this paper
• A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.

  2014cites this paper
• Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus

  2014cites this paper
• Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) Improves Glycemic Control After Meal Tolerance Test by Suppressing Glucagon Release

  2014cites this paper
• Original article: Efficacy and safety of voglibose as an add-on triple drug in patients of type two diabetes mellitus uncontrolled with glimepiride and metformin in punjabi population

  2014cites this paper
• Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials

  2014cites this paper
• Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".

  2014cites this paper
• Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by molecular field topology analysis.

  2014cites this paper
• Efficacy of voglibose in type 2 diabetes

  2014cites this paper
• Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study

  2013cites this paper
• Linagliptin provides effective, well‐tolerated add‐on therapy to pre‐existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes

  2013cites this paper
• The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes

  2013cites this paper
• Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

  2013cites this paper
• Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy.

  2013cites this paper
• Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes

  2013cites this paper
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes

  2013cites this paper
• Comparative Effectiveness Research/HTA Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

  2012cites this paper
• Efficacy and tolerability of vildagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes mellitus

  2012cites this paper
• Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

  2012cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

  2012cites this paper
• Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes

  2012cites this paper
• Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.

  2012cites this paper
• Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase

  2012cites this paper
• Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population

  2012cites this paper
• Vildagliptin

  2012influential citation
• Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

  2012cites this paper
• Comparative Effectiveness Research/Health Technology Assessment Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

  2012cites this paper
• Drug-induced hypoglycaemia in type 2 diabetes

  2012cites this paper
• Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study

  2012cites this paper
• Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

  2012cites this paper
• Efficacy and safety of saxagliptin in drug‐naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial

  2012cites this paper
• The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta‐analysis of randomized clinical trials

  2012cites this paper
• Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.

  2012cites this paper
• Vildagliptin DPP-4 inhibitor for the treatment of Type 2 diabetes Review

  2012cites this paper
• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  2011cites this paper
• Vildagliptin for the treatment of diabetes

  2011cites this paper
• Therapy in prac T ice

  2011cites this paper
• Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus

  2011cites this paper
• Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  2010influential citation
• D I a B E T E S & M E T a B O L I S M J O U R N a L the Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes Editorial Clinical Care/education

  year unknowncites this paper
• Vascular Health and Risk Management Dovepress Does the Treatment of Type 2 Diabetes Mellitus with the Dpp-4 Inhibitor Vildagliptin Reduce Hba1c to a Greater Extent in Japanese Patients than in Caucasian Patients?

  year unknowncites this paper